Clinical Trials in autoimmune PAP

IMPALA-2 Clinical Trial

The IMPALA-2 trial, a 48-week Phase 3 randomized, double-blind, placebo-controlled trial of MOLBREEVI* in 164 patients with autoimmune PAP is currently the largest controlled clinical trial in patients with autoimmune PAP. The trial was conducted in 16 countries, including the U.S., Canada, Japan, South Korea, Australia, and various European countries, including Turkey. Top line results from the trial were reported in June 2024 and can be found here. Additional data from the IMPALA-2 trial were presented at the European Respiratory Society (ERS) Congress in September 2024 and can be found on our Congresses and Publications page here and at other scientific meetings and congresses. Results from the IMPALA-2 Phase 3 clinical trial were also published in the New England Journal of Medicine (NEJM) in August 2025.

IMPALA Clinical Trial

The IMPALA trial was a 24-week, Phase 2/3 randomized, double-blind, placebo-controlled trial of MOLBREEVI in 138 patients with autoimmune PAP. The trial was conducted in 18 countries, including the U.S., Japan, and various European countries. Results from the trial were reported in June 2019 and were published in the New England Journal of Medicine (NEJM) in September 2020.

Savara thanks all the patients who participated in IMPALA and IMPALA-2.

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.